Business / NEWS UPDATE
L'Oreal says weight loss drugs are impacting beauty and skincare sales
Published · 1 min read
Beauty giant L'Oreal reports that weight loss drugs, particularly GLP-1s, are impacting sales of beauty and skincare products.
The company's CEO, Nicolas Hieronimus, noted this as a significant trend. L'Oreal is developing products to address side-effects like skin sagging from rapid weight loss and has increased its stake in dermatology firm Galderma. Both companies are testing products on GLP-1 users to address appearance changes.